Mode
Text Size
Log in / Sign up
N/A Completed N=100 Treatment

Prospective, Multi-center, Single-arm Study to Assess the Safety of Retrieval of the Recovery G2 Filter.

Chronic Obstructive Pulmonary Disease · Venous Thromboembolic Disease
Source: ClinicalTrials.gov NCT00556426 ↗
Enrolled (actual)
100
Serious AEs
6.0%
Results posted
May 2011
Primary outcomePrimary: Technical Success (Retrieval) — 58 participants

Summary

This study was designed to assess the safety of retrieval of the Bard Recovery® G2® Filter System. The G2 filter is an FDA-cleared device for inferior vena caval interruption in patients with pulmonary thromboembolism.

Outcome Measures

OutcomeResultp-value
PRIMARY
Technical Success (Retrieval)
58 —
PRIMARY
Clinical Success (Retrieval)
57 —
PRIMARY
Percentage of Participants With Adverse Events Through 30 Days Post Retrieval
14.8 —
SECONDARY
Filter Migration > 2cm
12.2 —
SECONDARY
Incidence of Filter Fracture
1 —

Eligibility Criteria

Inclusion Criteria

  • The patient is at temporary , increased risk of pulmonary embolism requiring caval interruption

Exclusion Criteria

  • The patient has implanted filter in the IVC or superior vena cava (SVC)
  • The patient has a duplicated or left-sided IVC
  • The patient has a known untreatable or uncontrollable malignancy
  • The patient has severe spinal deformity
  • The patient has a creatinine > 2.0 mg/dl
  • The patient has a life expectancy of < 6 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00556426). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search